Literature DB >> 9032887

The hemagglutination inhibition antibody responses to an inactivated influenza vaccine among healthy adults: with special reference to the prevaccination antibody and its interaction with age.

Y Hirota1, M Kaji, S Ide, S Goto, T Oka.   

Abstract

The immunogenicity of the trivalent split-virus influenza vaccine was investigated among 70 healthy adults (mean age: 48.5, range: 36-68). The vaccine antigens were: A/Yamagata/32/89 (H1N1); A/Beijing/352/89 (H3N2); and B/Bangkok/163/90. Regarding the entire sample, the vaccine induced a tenfold or more rise on the average in the hemagglutination inhibition (HAI) antibody to each antigen. The response rates (greater than or equal to a fourfold rise) were about 90% or more among those with a prevaccination titer < or = 1:64 (equivalent to < or = 1:16 on the Western scale; in Japan, the HAI titers are expressed by the final, and not the initial, dilution of the serum; from hereon our findings will be expressed using the Japanese scale), whereas they were 0-50% at > or = 1:128. Thus, the prevaccination titer was negatively associated with antibody induction. The achievement rates (postvaccination titer > or = 1:128) among those with a prevaccination titer < 1:16 remained at 48-68%. Regarding the analysis of variance, a significant effect on antibody induction was indicated for the prevaccination titer (P < or = 0.002), but not for age (P > or = 0.425). The interaction between the prevaccination titer and age was significant for A/Yamagata (P = 0.030), while it was also suggestive for A/Beijing (P = 0.054): as age increased, those with no preexisting antibody (< 1:16) showed greater titer rises, in contrast to the smaller rises among those with a titer > or = 1:16. Based on the attack survey conducted separately, the vaccine efficacy on influenza-like illnesses with fever < or = 37 degrees C and > or = 37.5 degrees C was calculated to be 16% (95% confidence interval: -66% to 57%) and 37% (-55% to 74%), respectively.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 9032887     DOI: 10.1016/s0264-410x(96)00153-3

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  14 in total

1.  Comparison of complement dependent lytic, hemagglutination inhibition and microneutralization antibody responses in influenza vaccinated individuals.

Authors:  Mary Dawn T Co; John Cruz; Akira Takeda; Francis A Ennis; Masanori Terajima
Journal:  Hum Vaccin Immunother       Date:  2012-08-16       Impact factor: 3.452

2.  Perspective on potential clinical applications of recombinant human interleukin-7.

Authors:  Claude Sportès; Ronald E Gress; Crystal L Mackall
Journal:  Ann N Y Acad Sci       Date:  2009-12       Impact factor: 5.691

3.  Trivalent influenza vaccine-induced antibody response to circulating influenza a (H3N2) viruses in 2010/11 and 2011/12 seasons.

Authors:  Satoshi Hiroi; Saeko Morikawa; Keiko Nakata; Akiko Maeda; Tsuneji Kanno; Shin Irie; Satoko Ohfuji; Yoshio Hirota; Tetsuo Kase
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

4.  Immunogenicity of the trivalent inactivated influenza vaccine in young children less than 4 years of age, with a focus on age and baseline antibodies.

Authors:  Ayumi Mugitani; Kazuya Ito; Shin Irie; Takashi Eto; Motoki Ishibashi; Satoko Ohfuji; Wakaba Fukushima; Akiko Maeda; Yoshio Hirota
Journal:  Clin Vaccine Immunol       Date:  2014-07-02

5.  Immunogenicity of a monovalent influenza A(H1N1)pdm09 vaccine in patients with hematological malignancies.

Authors:  Yuichiro Ide; Yutaka Imamura; Satoko Ohfuji; Wakaba Fukushima; Saburo Ide; Chiyo Tsutsumi; Masahisa Koga; Kazuhiro Maeda; Yoshio Hirota
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

Review 6.  Humoral immune response to influenza vaccination in patients from high risk groups.

Authors:  L B Brydak; M Machala
Journal:  Drugs       Date:  2000-07       Impact factor: 9.546

7.  Immunogenicity of a monovalent 2009 influenza A (H1N1) vaccine among pregnant women: lowered antibody response by prior seasonal vaccination.

Authors:  Satoko Ohfuji; Wakaba Fukushima; Masaaki Deguchi; Kazume Kawabata; Hideki Yoshida; Hideaki Hatayama; Akiko Maeda; Yoshio Hirota
Journal:  J Infect Dis       Date:  2011-05-01       Impact factor: 5.226

8.  Immunogenicity and Safety of Trivalent Split Influenza Vaccine in Healthy Korean Adults with Low Pre-Existing Antibody Levels: An Open Phase I Trial.

Authors:  Kyuri Kang; Seunghoon Han; Taegon Hong; Sangil Jeon; Jeongki Paek; Jin Han Kang; Dong Seok Yim
Journal:  Yonsei Med J       Date:  2016-11       Impact factor: 2.759

9.  Increased antibodies against unfolded viral antigens in the elderly after influenza vaccination.

Authors:  Upma Gulati; Wendy A Keitel; Gillian M Air
Journal:  Influenza Other Respir Viruses       Date:  2007-07       Impact factor: 4.380

10.  Intranasal vaccination with an inactivated whole influenza virus vaccine induces strong antibody responses in serum and nasal mucus of healthy adults.

Authors:  Akira Ainai; Shin-Ichi Tamura; Tadaki Suzuki; Elly van Riet; Ryo Ito; Takato Odagiri; Masato Tashiro; Takeshi Kurata; Hideki Hasegawa
Journal:  Hum Vaccin Immunother       Date:  2013-06-27       Impact factor: 3.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.